Advertisement
Advertisement
CytoDyn files $100M mixed securities shelf
PremiumThe FlyCytoDyn files $100M mixed securities shelf
4M ago
CytoDyn announces survival data in patients with mCRC treated with leronlimab
Premium
The Fly
CytoDyn announces survival data in patients with mCRC treated with leronlimab
5M ago
CytoDyn announces first patient dosed in Phase II oncology trial
Premium
The Fly
CytoDyn announces first patient dosed in Phase II oncology trial
5M ago
CytoDyn CEO writes March 2025 letter to shareholders
PremiumThe FlyCytoDyn CEO writes March 2025 letter to shareholders
8M ago
CytoDyn announces survival observations in mTNBC patients
Premium
The Fly
CytoDyn announces survival observations in mTNBC patients
9M ago
CytoDyn announces results from preclinical studies with SMC
Premium
The Fly
CytoDyn announces results from preclinical studies with SMC
9M ago
CytoDyn appoints Max Lataillade as head of clinical development
PremiumThe FlyCytoDyn appoints Max Lataillade as head of clinical development
1y ago
CytoDyn engages Syneos Health as CRO for Phase II oncology trial
Premium
The Fly
CytoDyn engages Syneos Health as CRO for Phase II oncology trial
1y ago
CytoDyn announces preliminary findings in study with SMC Laboratories
Premium
The Fly
CytoDyn announces preliminary findings in study with SMC Laboratories
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100